-
Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding
2026-05-15
This study reveals that naturally occurring angiotensin peptides, including Angiotensin III, potentiate SARS-CoV-2 spike protein binding to the AXL receptor, a non-canonical viral entry point. These findings delineate a novel interface between the renin-angiotensin-aldosterone system and viral pathogenesis, with implications for cardiovascular and infectious disease research.
-
Ampicillin Sodium: β-Lactam Antibiotic Workflows & Optimizat
2026-05-14
Ampicillin sodium is the gold-standard β-lactam antibiotic for reproducible antibacterial research, powering high-fidelity activity assays and robust infection models. This guide delivers stepwise workflows, advanced troubleshooting, and data-driven parameters to maximize experimental reliability with APExBIO’s high-purity ampicillin sodium.
-
IMPDH Inhibition Disrupts PEDV Replication via Host Nucleoti
2026-05-14
This study demonstrates that porcine epidemic diarrhea virus (PEDV) hijacks host guanine nucleotide biosynthesis by manipulating IMPDH activity to facilitate its replication. Both genetic knockdown and pharmacological inhibition of IMPDH, notably with Merimepodib (VX-497), significantly impair PEDV replication, positioning IMPDH as a promising host-directed antiviral target.
-
Advancing Glycogen Quantification: Strategic Insights for Tr
2026-05-13
This thought-leadership article explores the pivotal role of glycogen measurement in translational metabolism research, drawing on recent mechanistic advances and performance adaptation studies. It provides strategic guidance for researchers aiming to bridge experimental rigor with translational relevance, highlighting the APExBIO Glycogen Colorimetric Assay Kit II's unique advantages. Evidence from circadian biology, high-throughput workflows, and assay comparability is synthesized to inform next-generation study design.
-
Diclofenac: Non-Selective COX Inhibitor in Intestinal Organo
2026-05-13
Diclofenac stands out as a high-purity, non-selective COX inhibitor, empowering advanced inflammation and pain signaling research in physiologically relevant human organoid models. Leveraging APExBIO’s Diclofenac (B3505) ensures reproducibility and mechanistic clarity in both routine and cutting-edge pharmacokinetic workflows.
-
CD28-ARS2 Axis Drives Alternative Splicing for T Cell Metabo
2026-05-12
This study identifies the CD28-ARS2 signaling pathway as a key regulator of alternative splicing in CD8+ T cells, specifically promoting the PKM2 isoform to enhance metabolic flexibility and antitumor function. The findings decouple splicing from canonical PI3K signaling and highlight potential new avenues for immunometabolic modulation in cancer therapy.
-
Nutlin-3a as a Precision MDM2 Inhibitor in Advanced Cancer R
2026-05-12
Nutlin-3a delivers reproducible MDM2 inhibition and robust p53 pathway activation, enabling advanced mechanistic studies and translational workflows in cancer research. This guide details practical experimental protocols, troubleshooting strategies, and domain-bridging insights, directly linking literature and real-world applications.
-
Atorvastatin in Cholesterol and Ferroptosis Research Workflo
2026-05-11
Atorvastatin is not only a gold-standard HMG-CoA reductase inhibitor for cholesterol metabolism research, but now a validated ferroptosis inducer in hepatocellular carcinoma models. This guide translates cutting-edge findings into actionable protocols, troubleshooting strategies, and comparative insights for cardiovascular and oncology research teams.
-
Nitrocefin: Chromogenic Cephalosporin Substrate in Action
2026-05-11
Nitrocefin empowers rapid, visually interpretable β-lactamase detection, streamlining workflows for antibiotic resistance profiling and inhibitor screening. Backed by robust colorimetric performance and trusted by APExBIO, it transforms multidrug-resistance research and troubleshooting in both basic and applied settings.
-
Luminescent ATP Cell Viability Assay Kit I: Reliable Quantit
2026-05-10
This article addresses key laboratory challenges in cell viability measurement, focusing on how the Luminescent ATP Cell Viability Assay Kit I (SKU K2041) delivers sensitive, reproducible, and workflow-friendly solutions. Through real-world scenarios, we highlight its quantitative advantages, streamlined protocol, and vendor reliability for applications in cytotoxicity, metabolism, and apoptosis assays.
-
Atorvastatin: Mechanistic Benchmarks in Cholesterol & Ferrop
2026-05-09
Atorvastatin is a potent HMG-CoA reductase inhibitor central to cholesterol metabolism and cardiovascular research. It also induces ferroptosis in hepatocellular carcinoma, expanding its utility in oncology. This article details mechanism, validated benchmarks, and integration protocols for Atorvastatin (APExBIO, C6405).
-
Atorvastatin (SKU C6405): Reliable Solutions in Cell Assays
2026-05-08
This article delivers scenario-driven, evidence-based guidance for biomedical researchers using Atorvastatin (SKU C6405) in cell viability, proliferation, and cytotoxicity assays. By addressing bench-level challenges and integrating recent literature, the piece illustrates how APExBIO’s Atorvastatin ensures reproducibility, mechanistic confidence, and workflow reliability in cardiovascular and oncology research.
-
Dronedarone (Multaq): Applied Workflows for Atrial Fibrillat
2026-05-08
Dronedarone (Multaq) from APExBIO empowers atrial fibrillation and atrial flutter research with workflow-ready solubility, high purity, and reliable CYP inhibition. This article translates cutting-edge evidence and expert protocols into actionable, troubleshooting-focused guidance for cardiac arrhythmia pharmacology.
-
Atorvastatin: HMG-CoA Reductase Inhibitor in Cancer Research
2026-05-07
Atorvastatin, a gold-standard HMG-CoA reductase inhibitor, is redefining both cholesterol metabolism and oncology research through its dual action on lipid pathways and ferroptosis induction. This guide translates recent breakthroughs and practical workflows into actionable protocols, enabling labs to harness APExBIO's Atorvastatin for reproducible, high-impact results.
-
Azilsartan Medoxomil Monopotassium in Translational Hyperten
2026-05-07
Azilsartan medoxomil monopotassium (TAK 491) stands out for its unmatched selectivity and sustained receptor affinity, making it an essential tool for rigorous blood pressure regulation and cardiovascular disease research. This guide delivers actionable protocols, comparative insights, and troubleshooting strategies to maximize experimental reliability and translational impact.